Home buyers are overpaying mortgage fees. Shopping around can help.
Peer-Reviewed Publication
Updates every hour. Last Updated: 22-Nov-2025 00:11 ET (22-Nov-2025 05:11 GMT/UTC)
A combination of outreach methods – including texts, automated messages, and live phone calls – can significantly improve follow-up care for hard-to-reach patients after they have been discharged, according to a new nursing study from UCSF Health.
Cervical cancer will be the first human cancer eliminated through coordinated global action. A new special issue of Cancer Biology & Medicine brings together leading experts from around the world to examine progress, challenges, and innovations in prevention, screening, and treatment.
It’s boomtime for corporate psychedelia.
In the past few weeks, biotech startup MindMed secured $259m to fund its development pipeline, and competitors atai Life Sciences and Beckley Psytech merged to form AtaiBeckley.
Despite the hype around the benefits of psychedelics for mental health treatment, political economist Dr Sandy Brian Hager warns the “shroom boom” may be heading for a bust.
His study suggests investors could be spooked once more, because:
- Difficult to patent: Psychedelics cannot easily be patented, which turns off investors
- Unpredictable effects: Trips are subjective and can last up to 15 hours, complicating laboratory testing.
Pharma startups are responding by developing new classes of drugs:
- “Neuroplastogens”: All the warm and fuzzy feelings of connection without the hallucinations
- Ultra-short, intense trips: Newer compounds that cause very intense trips lasting only minutes, “at the time scale of a dental cleaning”.
For all the talk of a mental health revolution, psychedelics may deliver little more than business as usual, says Dr Hager.